Compare Global X Copper Miners ETF (COPX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Gilead Sciences, Inc. — how do they compare? Global X Copper Miners ETF trades at $89.15, while Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B). The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Global X Copper Miners ETF pays none, and Global X Copper Miners ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| COPX | GILD | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $155.80 |
52-Week Low | $46.08 | $110.56 |
Market Cap | — | $164.99B |
Enterprise Value | — | $188.06B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX, the Global X Copper Miners ETF, trades at $88.03, up 2.25% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides exposure to copper mining equities, which are leveraged to copper demand from AI data centers and electrification trends. Recent news highlights institutional accumulation and a buying opportunity after a pullback from 2026 highs.
The outlook is positive due to structural copper demand growth, though mining equities have underperformed copper futures year-to-date. Risks include commodity price volatility and supply bottlenecks. Analyst sentiment is bullish, emphasizing COPX as a pick-and-shovel play on AI infrastructure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
